Search Results

RAPT Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company’s Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma.

The regulator has placed a clinical hold on RAPT Therapeutics’ drug zelnecirnon, which was being investigated in atopic dermatitis and asthma, after a patient experienced liver failure.

RAPT Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2023.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced).

RAPT Therapeutics, Inc. today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations.